Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

Abstract Background Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK+ non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have demonstrated superiority compared to the fi...

Full description

Bibliographic Details

Published in:	BMC Cancer
Main Authors:	Petros Christopoulos, Farastuk Bozorgmehr, Lena Brückner, Inn Chung, Johannes Krisam, Marc A. Schneider, Albrecht Stenzinger, Regina Eickhoff, Daniel W. Mueller, Michael Thomas
Format:	Article
Language:	English
Published:	BMC 2021-06-01
Subjects:	Non-small cell lung cancer Anaplastic lymphoma kinase ALK+ NSCLC Tyrosine kinase inhibitors (TKI) Brigatinib Resistance mutations
Online Access:	https://doi.org/10.1186/s12885-021-08460-w